NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Syndax Pharmaceuticals, Inc. SNDX
12 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$172.4M
▲ 627.8% vs FY2024
EPS · FY25
$-3.29
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-161.8%
Net margin · FY25
-165.6%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 172.4M
Revenue, FY2025 · full 12-year series below
Revenue
Net income
The company lost 166 cents on every revenue dollar this year.
Per share
USD -3.29
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-161.8%
Return on equity, FY2025
ROE
Operating margin-158.4%
Net margin-165.6%
Return on assets-45.5%
Each USD of equity lost 162 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+157.7% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+157.7%
+75.4%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.09B
Shares outstanding, FY2025
Change, 5 years+82.5%
Change, 10 years—
The share count grew 83% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 529.7M
total assets, end of FY2025
Total assetsUSD 529.7M
EquityUSD 64.6M
CashUSD 134.9M
Gross debtUSD 350.0M
Net debtUSD 215.1M
Current ratio4.40×
Net debt stands at 333% of equity.
History
12 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Revenue $B
0.2
0.0
0.0
0.0
0.1
0.0
0.0
0.0
0.0
0.0
0.0
·
Operating income $B
−0.3
−0.3
−0.2
−0.2
0.0
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
EBITDA $B
−0.3
−0.3
−0.2
−0.1
0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
Income tax $B
0.0
·
·
·
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
Net income $B
−0.3
−0.3
−0.2
−0.1
0.0
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
EPS, diluted $
−3.29
−3.72
−2.98
−2.46
0.46
−1.87
−1.84
−2.92
−2.90
−3.22
−1519.27
−453.02
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−161.8
−75.7
−41.0
−34.1
7.5
−51.6
−132.4
−94.0
−64.5
·
·
·
Shares out B
0.09
0.09
0.08
0.07
0.05
0.05
0.03
0.02
0.02
0.02
0.00
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
34 of 34
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed